SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene and cell therapies, and consumer health products, today announced that it will release financial results for the third quarter of fiscal year 2021 ended March 31, 2021, before the market open on Tuesday, May 4, 2021. The Company’s management will host a webcast to discuss the results at 8:15 a.m. ET on the same day.
Catalent invites all interested parties to listen to the webcast, which will be accessible through Catalent’s website at http://investor.catalent.com.
A supplemental slide presentation will also be available in the “Investors” section of Catalent’s website prior to the start of the webcast.
The webcast replay, along with the supplemental slides, will be available for 90 days in the “Investors” section at www.catalent.com.
About Catalent, Inc.
Catalent, Inc. (NYSE: CTLT) is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 15,000 people, including over 2,400 scientists, at more than 45 facilities, and in fiscal 2020 generated over $3 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, please visit www.catalent.com.
More products. Better treatments. Reliably supplied.™